Experts released a new clinical guideline for effectively managing individuals diagnosed with hypertrophic cardiomyopathy (HCM). The guideline reiterates the importance of collaborative ...
Dec 27 (Reuters) - Cytokinetics (CYTK.O), opens new tab said on Wednesday that its experimental heart disease drug met the main goal of a keenly awaited late-stage study, putting it on track to ...
Hosted on MSN
These New Heart Meds Could Be Game Changers. Here's How to Know If They're Right for You.
NO MATTER HOW diligent you are about regular workouts and smart food choices, bad genes can overpower even the healthiest lifestyle, making heart medication essential. Though many people who come to ...
Cytokinetics aims to compete with a Bristol Myers Squibb heart drug projected to become a blockbuster seller, and the company’s value proposition is that its drug candidate has a potential safety edge ...
Bristol Myers Squibb BMY suffered a setback in the late-stage ODYSSEY-HCM study evaluating cardiovascular drug Camzyos (mavacamten). The phase III study was evaluating Camzyos for the treatment of ...
NEW YORK CITY — A class of drugs called beta-blockers — used for decades as a first-line treatment after a heart attack— doesn't benefit the vast majority of patients and may contribute to a higher ...
Novo Nordisk is adding on to its cardiovascular drug pipeline with the acquisition of Cardior Pharmaceuticals, a genetic medicines developer whose lead program is in mid-stage clinical testing in ...
Wegovy is part of a class of drugs called GLP-1 Receptor Agonists. Taking a weight loss drug may also help reduce the risk of heart attack, stroke and cardiac death, data shows. Wegovy, a drug ...
Share on Pinterest Combining GLP-1 drugs like Ozempic with SGLT2 diabetes medications may help reduce the risk of heart attacks, stroke, and kidney disease, new research suggests. Alexandr Muşuc/Getty ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback